Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419295 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
NCT07419295: Recruiting Phase 3 study, sponsored by Merck Sharp & Dohme.
NCT07419295 is a Phase 3 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 590 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07419295, a Phase 3 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Primary Outcome
OS is defined as time from randomization to death due to any cause.
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Vinflunine
- DRUG Rescue medications for sacituzumab tirumotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2030-04-23 |
| Phase | Phase 3 |
What NCT07419295 shows while recruiting
NCT07419295 is an interventional study that assigns participants to a tested intervention. The registered 590 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT07419295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07419295 about?
NCT07419295 is a clinical study titled "A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)". Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial me...
What is the current status of trial NCT07419295?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2026-04-23. Estimated completion is 2030-04-23.
What interventions are being tested in trial NCT07419295?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Docetaxel (DRUG), Paclitaxel (DRUG), Vinflunine (DRUG), Rescue medications for sacituzumab tirumotecan (DRUG).
Who is sponsoring clinical trial NCT07419295?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07419295's enrollment target sits among peer trials
590 643rd of 2000 higher than 1,356 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI